newsfilter
← Latest News
PR Newswire·

Tyra Biosciences to Present at the Cantor Global Healthcare Conference

  • Tyra Biosciences, Inc. (Nasdaq: TYRA) will participate in the Cantor Global Healthcare Conference 2026.
  • The event features a virtual fireside chat & one-on-one investor meetings scheduled for Wednesday, September 9, 2026, at 1:00 PM ET.
  • The presentation location is New York, NY, with a live webcast available via the company's investor page.
  • Tyra utilizes its SNÅP platform to design precision medicines targeting FGFR biology for oncology & genetically defined conditions.
  • The company's lead candidate, oral dabogratinib, is a selective FGFR3 inhibitor being developed for low-grade upper tract urothelial carcinoma, bladder cancer, & achondroplasia.
  • Tyra is also developing TYRA-430, an oral FGFR4/3-biased inhibitor, in the SURF431 study for advanced hepatocellular carcinoma.
  • TYRA-200, an oral FGFR1/2/3 inhibitor, is in the SURF201 study for metastatic intrahepatic cholangiocarcinoma.
  • Tyra Biosciences is based in Carlsbad, California.